Baker Avenue Asset Management, LP Macrogenics Inc Transaction History

Baker Avenue Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$5.2 - $29.12 $52,000 - $291,200	-10,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$4.28 - $12.11 $42,800 - $121,100	10,000 New	10,000 $58,000
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $79,500 - $122,700	-10,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $111,100 - $256,000	10,000 New	10,000 $179,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Baker Avenue Asset Management, LP with notifications on news.